secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2025-07-03T23:59:59+00:00
Accession:  0001104659-25-065781
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Iovance CFO Bellemin departs effective June 30; SVP Finance Rosinack named interim CFO
--------------------------------------------------------------------------------

- CFO Jean-Marc Bellemin's resignation accelerated from July 10 to June 30, 2025 by mutual agreement.
- Matthew W. Rosinack appointed interim Principal Financial Officer and Principal Accounting Officer effective June 30, 2025.
- Rosinack has been SVP, Finance since Sept 2021; prior roles at Berkeley Lights, ZELTIQ Aesthetics, FormFactor, and PwC.
- No arrangements, family relationships, or transactions requiring disclosure in connection with Rosinack's appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925065781/0001104659-25-065781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925065781/tm2519601d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-065781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer